{"SPADE_N_07227": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_07227", "Peptide Name": "Cyclic [W(RW)4 ]-Dox", "Source": "", "Family": "", "Gene": "Not found", "Sequence": "WRWRWRWRW", "Sequence Length": 9, "UniProt Entry": ["http://www.uniprot.org/uniprot/Notavailable"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Not available", "Hemolytic Activity": "Not available", "Cytotoxicity": "Not available", "Binding Target": "Not available", "Linear/Cyclic": "", "N-terminal Modification": "Free", "C-terminal Modification": "Dox, Doxorubicin", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C79H100N26O10", "Mass": 1573.81, "PI": 12.0, "Net Charge": 4, "Hydrophobicity": -2.5, "Half Life": "Mammalian:2.8 hourYeast:3 minE.coli:2 min", "Literature": [{"Title": "Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs.", "Pubmed ID": "23301519", "Reference": "Mol Pharm. 2013 Feb 4;10(2)488-99.", "Author": "Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Parang K.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=23301519"}], "Frequent Amino Acids": "WR", "Absent Amino Acids": "ACDEFGHIKLMNOPQSTUVY", "Basic Residues": 4, "Acidic Residues": 0, "Hydrophobic Residues": 5, "Polar Residues": 4, "Positive Residues": 4, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_08428", "Similarity": 1.0, "Sequence": "RWRWRWFGGGFIKHFIHRF"}, {"SPADE_ID": "SPADE_N_08429", "Similarity": 1.0, "Sequence": "RWRWRWFSGGFIKHFIHRF"}, {"SPADE_ID": "SPADE_N_08430", "Similarity": 1.0, "Sequence": "RWRWRWFSATFIKHFIHRF"}]}}}